News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

Sign In

Study Hints at Clinical Lab’s Future Role in Investigating Sudden Unexplained Death in Children

UW Medicine and Seattle Children’s launch long-read sequencing research to uncover genetic factors, setting new standards for pediatric genomic testing.

The Sudden Unexplained Death in Childhood (SUDC) Foundation has awarded funding to a team at UW Medicine and Seattle Children’s Hospital to use PacBio HiFi long-read sequencing as a first-line tool to investigate cases of SUDC.

The study represents a critical step in both research and clinical laboratory practice. Applying long-read sequencing as a first-tier assay can streamline workflows, particularly when working with challenging samples such as post-mortem tissue or dried blood spots. Laboratories involved will need to combine advanced sequencing with robust bioinformatics pipelines, accurate variant interpretation, and integration of parental genomes to provide clinically relevant results.

The study, led by Danny E. Miller, MD, PhD, assistant professor of pediatrics and laboratory medicine and pathology at the University of Washington, and Alexandra Keefe, MD, PhD, assistant professor of pediatrics at UW Medicine, will sequence 200 family trios—a child and their parents—aiming to uncover genetic factors that may contribute to these sudden, unexplained deaths.

PacBio’s Revio system with SPRQ-Nx chemistry will be used to generate highly accurate long-read genomes, allowing researchers to detect complex structural variants and tandem repeats that traditional sequencing may miss. By including parental data, the team hopes to distinguish inherited variants from spontaneous mutations, increasing the likelihood of actionable findings for families.

Long-Read Sequencing Advances SUDC Investigations

“Selecting HiFi sequencing as our first-line whole-genome assay allows us to search for answers with the accuracy and breadth these families deserve,” said Miller. “By starting with long reads and incorporating parental data, we can resolve difficult variants, phase them accurately, and provide guidance relevant to SUDC.”

The SUDC Foundation currently assists over 1,000 families in more than 20 countries. The organization emphasizes the importance of comprehensive investigations for sudden child deaths, including genetic testing, DNA banking, and family screening when appropriate.

“Families affected by SUDC face unimaginable loss,” said Julia Burgess, president of the SUDC Foundation. “Funding this project reflects our commitment to advancing research that brings clarity, guidance, and hope to grieving families nationwide.”

Beyond supporting families, the research could establish a model for how cutting-edge genomic testing is incorporated into clinical investigations of sudden childhood deaths. The team plans to implement a tiered genomic approach for cases with suspected genetic causes, beginning with trio-based exome and low-pass whole-genome sequencing, followed by reflexive long-read sequencing when necessary.

“This project has the potential not only to provide answers to families but also to transform standards for genetic investigation in pediatric sudden death,” said Keefe. “It highlights the essential role laboratories play in turning advanced genomic technologies into actionable clinical knowledge.” (Photo credit: UW Medicine)

The SUDC Foundation expects the study, funded at $328,133 over four years, to generate data that supports broader adoption of long-read sequencing in pediatric genomics and enhance understanding of the genetic underpinnings of SUDC.

For clinical laboratory professionals, this initiative underscores the growing expectation that advanced genomic technologies—particularly long-read whole-genome sequencing and trio analysis—will play a larger role in investigating unexplained pediatric deaths. As these tools move toward first-line use, labs must be prepared to support complex variant detection, robust bioinformatics interpretation, and collaboration with clinicians and medical examiners, positioning the laboratory at the center of efforts to deliver clearer answers for families.

—Janette Wider

CDC Traveler-Based Genomic Surveillance Program Tops One Million Participants, Giving Clinical Labs Earlier Warning on Emerging Variants

The CDC’s Traveler-Based Genomic Surveillance program has surpassed one million voluntary participants, strengthening border-based genomic monitoring that helps clinical, molecular, and public health laboratories detect emerging variants—often days before they appear in community testing, hospital admissions, or public sequence databases.

The CDC announced that its Traveler-Based Genomic Surveillance (TGS) program has surpassed one million voluntary participants, marking a significant expansion of the nation’s upstream pathogen surveillance infrastructure. For clinical, molecular, and public health laboratories, the milestone highlights how border-based genomic monitoring is increasingly being used to identify emerging variants before they appear in community testing or hospital admissions.

Launched in 2021, TGS collects anonymous nasal swabs from arriving international travelers at select U.S. airports and complements this data with aircraft wastewater sampling. Sequencing and analysis are conducted through public-private partnerships with companies such as Ginkgo Biosecurity and XWell, allowing the CDC to generate actionable genomic data even when testing and sequencing capacity may be limited in other parts of the world. The approach reflects a shift toward proactive surveillance models that rely on rapid sequencing and data sharing rather than traditional case-based reporting alone.

Photo credit: CDC

In 2023, Dark Daily reported that San Francisco International Airport became the first US airport to partner with the CDC to test aircraft wastewater for SARS-CoV-2, sending samples to clinical laboratories for PCR testing and genomic sequencing as an early warning system for emerging variants.

Early Genomic Signals Give Laboratories Critical Lead Time on Emerging Variants

CDC officials say the program has already demonstrated practical value for laboratories. In one example, TGS identified new influenza H3N2 subclades and submitted sequences to public databases several days before they were detected elsewhere. For laboratory leaders, early awareness of emerging variants can inform assay validation, test menu planning, reagent procurement, and staffing decisions—particularly during respiratory virus season when demand can shift quickly.

The program also signals a growing role for nontraditional specimen sources in public health surveillance. In addition to traveler samples, CDC has analyzed more than 2,600 aircraft wastewater samples, reinforcing interest in wastewater-based epidemiology as a complementary tool for laboratories and public health agencies seeking earlier signals of emerging threats.

Participation in TGS remains voluntary and anonymous, but its scale suggests increasing acceptance of genomic surveillance as part of routine public health operations. For laboratories, the program offers a preview of how future surveillance systems may operate—integrating high-throughput sequencing, public-private partnerships, and unconventional sampling to deliver earlier warning of pathogens likely to impact diagnostic testing and clinical workflows nationwide.

—Janette Wider

;